This company listing is no longer active
21J Stock Overview
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Jounce Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.67 |
52 Week High | US$5.13 |
52 Week Low | US$0.53 |
Beta | 0.75 |
1 Month Change | -3.47% |
3 Month Change | 61.43% |
1 Year Change | -64.83% |
3 Year Change | -62.22% |
5 Year Change | -88.59% |
Change since IPO | -89.23% |
Recent News & Updates
Recent updates
Shareholder Returns
21J | DE Biotechs | DE Market | |
---|---|---|---|
7D | -3.5% | 3.3% | 1.6% |
1Y | -64.8% | 35.8% | 6.4% |
Return vs Industry: 21J underperformed the German Biotechs industry which returned -5.2% over the past year.
Return vs Market: 21J underperformed the German Market which returned -3.3% over the past year.
Price Volatility
21J volatility | |
---|---|
21J Average Weekly Movement | 19.8% |
Biotechs Industry Average Movement | 5.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 21J's share price has been volatile over the past 3 months.
Volatility Over Time: 21J's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 141 | n/a | https://jouncetx.com |
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy.
Jounce Therapeutics, Inc. Fundamentals Summary
21J fundamental statistics | |
---|---|
Market cap | €89.78m |
Earnings (TTM) | -€46.20m |
Revenue (TTM) | €74.40m |
1.2x
P/S Ratio-1.9x
P/E RatioIs 21J overvalued?
See Fair Value and valuation analysisEarnings & Revenue
21J income statement (TTM) | |
---|---|
Revenue | US$82.00m |
Cost of Revenue | US$54.80m |
Gross Profit | US$27.20m |
Other Expenses | US$78.12m |
Earnings | -US$50.92m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.97 |
Gross Margin | 33.17% |
Net Profit Margin | -62.10% |
Debt/Equity Ratio | 0% |
How did 21J perform over the long term?
See historical performance and comparison